NCT03802695View on ClinicalTrials.gov

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 8, 2019

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesMixed Phenotype Acute Leukemia
Interventions
BIOLOGICAL

OrcaGraft (Orca-Q)

engineered donor allograft

Trial Locations (8)

30322

ACTIVE_NOT_RECRUITING

Emory University, Atlanta

43210

ACTIVE_NOT_RECRUITING

Ohio State University, Columbus

53226

WITHDRAWN

Froedtert Memorial Lutheran Hospital, Milwaukee

66160

WITHDRAWN

The University of Kansas Hospital, Kansas City

77054

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

94305

RECRUITING

Stanford Health Care, Stanford

95817

RECRUITING

UC Davis, Sacramento

Sponsors
All Listed Sponsors
lead

Orca Biosystems, Inc.

INDUSTRY